ADXS
Analistos consideran que la subvención de hoy que sube tres pavos la valoración de la empresa. Los 20 de las opciones del viernes que yo decía :D
FDA OOPD Award Seen as Incremental Positive for Advaxis (ADXS) - FBR
FBR & Co. affirms Advaxis (Nasdaq: ADXS) at Outperform after the company announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development (OOPD) awarded a grant totaling $1.1 million over three years to Baylor College of Medicine in support of an ongoing Phase 2 trial of Advaxis's lead Lm Technology immunotherapy, axalimogene filolisbac (ADXS-HPV), in HPV-associated oropharynx (throat) cancer, a type of head and neck cancer.
Analyst Vernon T. Bernardino commented, "We view the award as an incremental positive, as it provides near-term funds, and importantly, strongly validates the evaluation of axalimogene filolisbac, which we estimate contributes at least $3 in value per share, as a potential treatment for improving outcomes with standard care in HPV-associated head and neck cancers. We believe ADXS shares are attractively valued and therefore reiterate our Outperform rating."
http://www.streetinsider.com/Analyst+Comments/FDA+OOPD+Award+Seen+as+Incremental+Positive+for+Advaxis+%28ADXS%29+-+FBR/10889069.html?si_client=intbro
«Después de nada, o después de todo/ supe que todo no era más que nada.»